Skip to main content

Sun Pharmaceutical Industries Ltd.

₹1,757.5

6.3 (0.4%)stock indicator image for upward trend

SUNPHARMA Share Price
As on October 28, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap₹ 4,21,803 Cr
P/E Ratio36.73
Dividend Yield0.91 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open1,754.9
High1,764
NSE SymbolSUNPHARMA
Close1,757.5
Low1,726.2
BSE Symbol524715
Previous Years High/Low
1 Year High2,046.9
3 Year High2,046.9
5 Year High2,046.9
1 Year Low1,583.7
3 Year Low1,068.35
5 Year Low733.7

Technicals


IndicatorsValueSignal
5-DMA1,750.94Bullish
10-DMA1,751.2Bullish
20-DMA1,770.5Bearish
50-DMA1,839.18Bearish
100-DMA1,870.56Bearish
200-DMA1,808.43Bearish

Historical Performance


1 Year
4.2%
3 Years
58.1%
5 Years
117.6%
10 Years
136.4%

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2026Mar-2025Mar-2024Mar-2023Mar-2022
Net Sales5,84,6205,25,7844,84,9684,38,8573,86,545
Total Expenditure4,19,7083,74,9233,57,4783,22,9812,87,727
Other Income32,11921,50616,2826,93814,374
Operating Profit1,97,0311,72,3671,43,7731,22,8131,13,192
Interest3,3892,3142,3851,7201,274
Depreciation29,37825,75425,56625,29421,437
Profit Before Tax1,51,1891,37,5211,10,87994,08444,813
Consolidated Net Profit1,14,7941,09,29095,76484,73632,727
Adjusted EPS4846403514
Compounded Sales Growth
10 Years:15.8
5 Years:11.8
3 Years:5.9
TTM:2.1
Compounded Profit Growth
10 Years:20.4
5 Years:31.6
3 Years:6.3
TTM:1
Stock Price CAGR
10 Years:9
5 Years:17.2
3 Years:16.5
TTM:2.4
Return on Equity
10 Years:29
5 Years:13.6
3 Years:39.9
last year:47.8

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2026Mar-2025Mar-2024Mar-2023Mar-2022
Share Capital2,3992,3992,3992,3992,399
Total Reserves8,33,3027,19,7816,34,2685,57,5544,77,713
Long-Term Borrowings---------------
Total Non-Current Liabilities-17,630-29,871-27,143-19,978-13,164
Other Current Liabilities39,43832,54427,16826,03529,267
Short Term Borrowings40,50418,67128,44459,5834,685
Total Liabilities10,47,3888,76,9308,13,9607,72,2476,69,582
Capital Work in Progress13,80612,34311,0779,6347,975
Long Term Loans & Advances11,32810,16527,84627,57928,809
Currents Investments2,09,3341,36,56185,84593,72676,339
Short Term Loans and Advances36,06036,92424,54220,21620,126
Total Current Assets6,38,6035,25,9414,34,3313,98,6193,48,646
Total Assets10,47,3888,76,9308,13,9607,72,2476,69,582
Adjusted Book Value348301265233200
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 36.73, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 16.4%, indicating sustained price appreciation.
  • The stock carries a low beta of 0.4, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹197031 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹584620 million, indicating a large and established business.

Investment Calculator


₹
Investment Amount: ₹ 1000000
Current Value: ₹ 1024243.8
No. of Shares: 583 (Approx)
Performance:2.4%
24243.8
NIFTY Performance: -12.9%
1 day Top Gainers
SymbolChange%
PPLPHARMA232.8(17%)
SYNGENE410.85(12%)
SBFC90.49(10%)
PGEL536.4(7%)
ZEEL69.09(7%)
1 Day Top Losers
SymbolChange%
MRPL172.9(-9%)
CONCORDBIO1268.5(-8%)
TTML39.23(-6%)
KAYNES3140(-6%)
AWL165.49(-6%)
JUBLINGREA593.6(-6%)
SAIL162(-5%)
STARHEALTH519.25(-5%)

Top Performing Stocks from the same sector


Bafna Pharmaceuticals Ltd.

▲ 26.5%

₹ 451.6

1 Month Performance

Acutaas Chemicals Ltd.

▲ 15.4%

₹ 3710

1 Month Performance

Piramal Pharma Ltd.

▲ 12.7%

₹ 232.8

1 Month Performance

FDC Ltd.

▲ 9.6%

₹ 376.55

1 Month Performance

Dr. Reddy's Laboratories Ltd.

▲ 9.4%

₹ 1335.4

1 Month Performance

Aarey Drugs & Pharmaceuticals Ltd.

▲ 8.6%

₹ 108.05

1 Month Performance

Laurus Labs Ltd.

▲ 8.5%

₹ 2181.9

1 Month Performance

Brooks Laboratories Ltd.

▲ 5.9%

₹ 59.9

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month

Latest News

Stay Updated with Our Market Newsletters

Article Image: 8 Fundamental Indicators for Stocks in 2026

January 13, 2025 | 7 min read

8 Fundamental Indicators for Stocks in 2026

Article Image: How to Research Stocks Like a Pro: Tools and Resources

October 31, 2024 | 4 min read

How to Research Stocks Like a Pro: Tools and Resources

Article Image: 8 Common Investment Jargons You Should Know

January 1, 2021 | 2 min read

8 Common Investment Jargons You Should Know

Article Image: Stock Market for Beginners: 10 Tips to Keep in Mind

November 25, 2024 | 8 min read

Stock Market for Beginners: 10 Tips to Keep in Mind

Article Image: How to Choose the Right Stocks: The Ultimate Guide

November 15, 2024 | 4 min read

How to Choose the Right Stocks: The Ultimate Guide

Article Image: The Role of Stock Market Advisory in Maximizing Returns

December 19, 2024 | 3 min read

The Role of Stock Market Advisory in Maximizing Returns